{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-25-000088","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.956965+00:00","generated_at":"2026-05-23T00:30:12.111634+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Summit Therapeutics Q1 net loss widens to $62.9M; ivonescimab gets second China approval","bullets":["GAAP net loss $62.9M ($0.09/share) vs $43.5M ($0.06) in Q1 2024; R&D expenses rose to $51.2M.","Cash and investments $361.3M at Mar 31, 2025 vs $412.3M at Dec 31, 2024; non-GAAP op expenses $55.7M.","Ivonescimab showed statistically significant PFS superiority vs tislelizumab in HARMONi-6 trial (squamous NSCLC).","China NMPA approved ivonescimab for second indication (1L NSCLC with PD-L1+); interim OS HR=0.777.","Appointed Robert LaCaze as CCO; enrollment ongoing in HARMONi-3 and HARMONi-7; HARMONi topline expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-25-000088","json":"https://secwatch.observer/filing/0001599298-25-000088.json","markdown":"https://secwatch.observer/filing/0001599298-25-000088.md","text":"https://secwatch.observer/filing/0001599298-25-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000088/0001599298-25-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000088/smmt-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:30:12.111634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}